Axsome Therapeutics Inc (NASDAQ:AXSM) — Market Cap & Net Worth
Market Cap & Net Worth: Axsome Therapeutics Inc (AXSM)
Axsome Therapeutics Inc (NASDAQ:AXSM) has a market capitalization of $11.22 Billion ($11.22 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2025 globally and #759 in its home market, demonstrating a -9.75% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Axsome Therapeutics Inc's stock price $217.99 by its total outstanding shares 51459766 (51.46 Million). See AXSM capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Axsome Therapeutics Inc Market Cap History: 2015 to 2026
Axsome Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $477.03 Million to $11.22 Billion (35.05% CAGR).
Index Memberships
Axsome Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.46% | #37 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.03% | #229 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.65% | #27 of 263 |
Weight: Axsome Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Axsome Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Axsome Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.72x
Axsome Therapeutics Inc's market cap is 14.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.94 Billion | $8.82 Million | -$134.94 Million | 220.43x | N/A |
| 2022 | $3.97 Billion | $50.04 Million | -$187.13 Million | 79.32x | N/A |
| 2023 | $4.10 Billion | $270.60 Million | -$239.24 Million | 15.14x | N/A |
| 2024 | $4.35 Billion | $385.69 Million | -$287.22 Million | 11.29x | N/A |
| 2025 | $9.40 Billion | $638.50 Million | -$183.17 Million | 14.72x | N/A |
Competitor Companies of AXSM by Market Capitalization
Companies near Axsome Therapeutics Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Axsome Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Axsome Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Axsome Therapeutics Inc's market cap moved from $477.03 Million to $ 11.22 Billion, with a yearly change of 35.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.22 Billion | +19.36% |
| 2025 | $9.40 Billion | +115.86% |
| 2024 | $4.35 Billion | +6.31% |
| 2023 | $4.10 Billion | +3.19% |
| 2022 | $3.97 Billion | +104.16% |
| 2021 | $1.94 Billion | -53.63% |
| 2020 | $4.19 Billion | -21.18% |
| 2019 | $5.32 Billion | +3565.25% |
| 2018 | $145.12 Million | -49.64% |
| 2017 | $288.17 Million | -17.04% |
| 2016 | $347.35 Million | -27.18% |
| 2015 | $477.03 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Axsome Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.22 Billion USD |
| MoneyControl | $11.22 Billion USD |
| MarketWatch | $11.22 Billion USD |
| marketcap.company | $11.22 Billion USD |
| Reuters | $11.22 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more